Discriminating in favour of or against men with increased risk of finasteride‐related side effects?

  title={Discriminating in favour of or against men with increased risk of finasteride‐related side effects?},
  author={R. Tr{\"u}eb},
  journal={Experimental Dermatology},
  • R. Trüeb
  • Published 2017
  • Biology, Medicine
  • Experimental Dermatology
  • Based on observations of Julianne Imperato-McGinley of Cornell Medical College, New York presented at a conference on birth defects in 1974 on a peculiar genetic disorder due to type 2 5α-reductase deficiency (5-ARD), oral finasteride was approved in 1992 by the U.S. Food and Drug Administration for treatment of benign prostatic hyperplasia (BPH), and in 1997 for treatment of male pattern baldness (MPB). 
    2 Citations
    A Comment on the Post-Finasteride Syndrome
    • 6
    The postfinasteride syndrome; an overview
    • 16


    Evaluation of efficacy and safety of finasteride 1 mg in 3177 Japanese men with androgenetic alopecia
    • 31
    • PDF
    Persistent sexual side effects of finasteride: could they be permanent?
    • 39
    • Highly Influential
    Psychosexual Characteristics of Men and Women Exposed Prenatally to Diethylstilbestrol
    • 53
    Second to fourth digit length ratio (2D:4D) and adult sex hormone levels: New data and a meta-analytic review
    • 294
    • PDF
    Psychiatric comorbidity in gender identity disorder.
    • 202
    Are hand preference and sexual orientation possible predicting factors for finasteride adverse effects in male androgenetic alopecia? Exp Dermatol 2016
    • 2016
    Guide to Successful Management
    • 2014